Navigation Links
Xencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research (AACR) 2017 Annual Meeting

MONROVIA, Calif., March 1, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of inflammation and cancer, today announced that data from preclinical studies on XmAb®18087 and additional candidates deploying its XmAb® bispecific and half-life extension technology will be presented during presentations at the American Association for Cancer Research (AACR) 2017 Annual Meeting taking place April 1-5, 2017.

Abstracts are available on the AACR conference website at Information contained in the abstract was at the time of submission in November 2016. An updated data set will be presented at the AACR Annual Meeting in April.  

Title: 3633. Anti-SSTR2 × anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors
Presenter/Authors: Sung-Hyung Lee, Seung Y. Chu, Rumana Rashid, Sheryl Phung, Irene W. L. Leung, Umesh S. Muchhal, Gregory L. Moore, Matthew J. Bernett, Suzanne Schubbert, Connie Ardila, Christine Bonzon, Paul Foster, David E. Szymkowski, John R. Desjarlais. Xencor, Monrovia, CA
Session: BITES Bispecifics and Checkpoints
Session date and time: Tuesday, April 4, 2017, 8:00 - 12:00 PM

  • Anti-SSTR2 × anti-CD3 affinity-optimized bispecific antibody produced using Xencor's bispecific platform
  • The goal is to assess XmAb18087 pharmacology in cynomolgus monkeys
  • T cell activation, extravasation, and cytokine induction were readily measured in peripheral blood and are indicative of SSTR2-mediated T cell activation in vivo
  • Results on human cells, in mice, and in monkeys support clinical assessment of XmAb18087 in SSTR2+ cancers including neuroendocrine tumors and small cell lung cancer

Title: 1639. Combination of PD1 blockade and T cell costimulation by bispecific antibodies promotes human T cell activation and proliferation
Presenter/Authors: Gregory L. Moore, Michael Hedvat, Matthew J. Bernett, Rajat Varma, Suzanne Schubbert, Christine Bonzon, Kendra N. Avery, Rumana Rashid, Alex Nisthal, Liz Bogaert, Irene W. L. Leung, Seung Y. Chu, Umesh S. Muchhal, John R. Desjarlais. Xencor, Inc., Monrovia, CA
Session: Tumor Microenvironment and Checkpoints
Session date and time: Monday, April 3, 2017, 8:00 - 12:00 PM

  • Bispecific antibody targeting PD1 and an undisclosed co-stimulatory receptor (PD1 x costim) produced using Xencor's bispecific platform
  • Goal is to engage co-stimulatory receptors in combination with checkpoint blockade to increase T cell activation and improve patient response rate
  • Compelling activity suggests clinical development is warranted for the treatment of human malignancies

Title: 1595. IL15/IL15Ra heterodimeric Fc-fusions with extended half-lives 
Presenter/Authors: Matthew J. Bernett, Christine Bonzon, Rumana Rashid, Rajat Varma, Kendra N. Avery, Irene W. L. Leung, Seung Y. Chu, Umesh S. Muchhal, Gregory L. Moore, John R. Desjarlais. Xencor, Inc., Monrovia, CA
Session: Cytokines: The First Modern Immunotherapies 
Session date and time: Monday, April 3, 2017, 8:00 - 12:00 PM

  • IL15/IL15Ra heterodimeric Fc-fusions produced using Xencor's XmAb® bispecific and half-life extension technology
  • The Fc-fusions enhanced proliferation of T and NK cells in vitro and in vivo, and prolonged half-life
  • Data indicate that IL15/IL15Ra heterodimeric Fc-fusions demonstrate the high activity of IL15 with a more favorable PK profile

About Xencor, Inc. 
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, 11 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internal programs include: XmAb5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb7195 in Phase 1 development for the treatment of asthma and allergic diseases; XmAb14045 in Phase 1 development for acute myeloid leukemia; XmAb13676 in Phase 1 development for B-cell malignancies; and XmAb18087 for the treatment of neuroendocrine tumors, in pre-clinical development. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action.  Xencor partners include Novartis, Amgen, MorphoSys, Merck, CSL/Janssen, Alexion and Boehringer Ingelheim. For more information, please visit

Forward Looking Statements:
Statements contained in this press release and the related abstracts and presentations regarding matters that are not historical facts are forward-looking statements within the meaning of applicable securities laws, including any expectations relating to our business, research and development programs, including XmAb®18087 and other bispecific antibody candidates, partnering efforts or our capital requirements. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics and other risks described in Xencor's public securities filings. All forward-looking statements are based on Xencor's current information and belief as well as assumptions made by Xencor. Readers are cautioned not to place undue reliance on such statements and Xencor disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


To view the original version on PR Newswire, visit:

SOURCE Xencor, Inc.
Copyright©2017 PR Newswire.
All rights reserved

Related biology technology :

1. Xencor Reports Fourth Quarter and Full Year 2016 Financial Results
2. Xencor to Present at Leerink Partners 6th Annual Global Healthcare Conference
3. Xencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and Systemic Lupus Erythematosus
4. Xencor to Present at Credit Suisse 24th Annual Healthcare Conference
5. Xencor Reports Third Quarter 2015 Financial Results and Pipeline Update
6. Xencor to Host R&D Day and Webcast on June 26, 2015
7. Xencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory Affairs and Wayne Saville, M.D., as Vice President of Clinical Oncology
8. Xencor, Inc. Announces Proposed Public Offering of Common Stock
9. Xencor to Webcast Presentations at Two Upcoming Conferences in February
10. Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel
11. Xencor Prices Initial Public Offering
Post Your Comments:
(Date:7/9/2019)... ... July 08, 2019 , ... Today, at the BIO ... National Corn Growers Association (NCGA) announced the winners of the Consider Corn Challenge ... or process using field corn to produce biobased materials. , “Corn is a ...
(Date:6/26/2019)... LAS VEGAS (PRWEB) , ... June 26, 2019 , ... ... biofield energy treatment on improving physicochemical properties of Magnesium Gluconate, which can prove to ... Over 125% alteration of characteristic differentiation peak, change in crystallite size , ...
(Date:6/12/2019)... (PRWEB) , ... June 12, 2019 , ... ... built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food ... Zillion has been signed. The agreement will grant exclusive rights for Zillion to ...
(Date:6/11/2019)... ... 10, 2019 , ... DeepDyve and IOP ... to DeepDyve’s rental service for peer-reviewed journals. , IOPP’s portfolio represents an ... 20 million articles, sourced from more than 15,000 journals. , “By partnering with ...
Breaking Biology Technology:
(Date:8/21/2019)... ... August 20, 2019 , ... Cutting Edge ... for the spine, today announced the 510(K) clearance of its novel SI joint ... is proven to improve osseointegration through superior hydrophilicity and optimized surface chemistry, as ...
(Date:8/15/2019)... ... 2019 , ... Deep Science Ventures (DSV), a new paradigm for ... unit dedicated to building 100 companies over the next 10 years to address the ... , Deep Science Ventures was founded to create a better method for launching science ...
(Date:8/14/2019)... ... August 14, 2019 , ... An ... how developments in microbiome therapeutics are helping to promote normal immune function in ... , Advancements will educate about the DECODE.DESIGN.CURE™ technology platform, which rapidly develops microbiome ...
Breaking Biology News(10 mins):